Evidence mapPaperPMID 28733906Full record

ArticleDiabetologia2017

The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass.

Judith Aron-Wisnewsky, Nataliya Sokolovska, Yuejun Liu, Doron S Comaneshter, Shlomo Vinker, Tal Pecht, Christine Poitou, Jean-Michel Oppert, Jean-Luc Bouillot, Laurent Genser and 4 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 5 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 5 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Precision Medicine in Bariatric Procedures.Gastrointestinal endoscopy clinics of North America · 2024
    Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Judith Aron-WisnewskyInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Nataliya SokolovskaInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Yuejun LiuInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Doron S ComaneshterCentral Headquarters, Clalit Health Services, Tel Aviv, Israel.
Shlomo VinkerCentral Headquarters, Clalit Health Services, Tel Aviv, Israel.
Tal PechtDepartment of Clinical Biochemistry and Pharmacology at the Faculty of Health Sciences and the National Institute of Biotechnology in the Negev (NIBN), Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Christine PoitouInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Jean-Michel OppertInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Jean-Luc BouillotSurgery Department, Assistance Publique - Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne-Billancourt, France.
Laurent GenserHepato-biliary and Digestive Surgery Department, Assistance Publique - Hôpitaux de Paris, Pitié-Salpétrière Hospital, Paris, France.
Dror DickerSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jean-Daniel ZuckerInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France.
Assaf RudichDepartment of Clinical Biochemistry and Pharmacology at the Faculty of Health Sciences and the National Institute of Biotechnology in the Negev (NIBN), Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Karine ClémentInstitute of Cardiometabolism and Nutrition (ICAN), Nutrition Department, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 46-83 Boulevard de l'Hôpital, F-75013, Paris, France. karine.clement@psl.aphp.fr.
Sorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRBen-Gurion University of the Negev · ILClalit Health Services · ILFondation pour l’innovation en Cadiométabolisme et Nutrition · FRNutrition et obésité : approches systémiques · FRPitié-Salpêtrière Hospital · FRTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisNot all people with type 2 diabetes who undergo bariatric surgery achieve diabetes remission. Thus it is critical to develop methods for predicting outcomes that are applicable for clinical practice. The DiaRem score is relevant for predicting diabetes remission post-Roux-en-Y gastric bypass (RYGB), but it is not accurate for all individuals across the entire spectrum of scores. We aimed to develop an improved scoring system for predicting diabetes remission following RYGB (the Advanced-DiaRem [Ad-DiaRem]).

methodsWe used a retrospective French cohort (n = 1866) that included 352 individuals with type 2 diabetes followed for 1 year post-RYGB. We developed the Ad-DiaRem in a test cohort (n = 213) and examined its accuracy in independent cohorts from France (n = 134) and Israel (n = 99).

resultsAdding two clinical variables (diabetes duration and number of glucose-lowering agents) to the original DiaRem and modifying the penalties for each category led to improved predictive performance for Ad-DiaRem. Ad-DiaRem displayed improved area under the receiver operating characteristic curve and predictive accuracy compared with DiaRem (0.911 vs 0.856 and 0.841 vs 0.789, respectively; p = 0.03); thus correcting classification for 8% of those initially misclassified with DiaRem. With Ad-DiaRem, there were also fewer misclassifications of individuals with mid-range scores. This improved predictive performance was confirmed in independent cohorts. CONCLUSIONS/

interpretationWe propose the Ad-DiaRem, which includes two additional clinical variables, as an optimised tool with improved accuracy to predict diabetes remission 1 year post-RYGB. This tool might be helpful for personalised management of individuals with diabetes when considering bariatric surgery in routine care, ultimately contributing to precision medicine.

Indexed as

Gastric BypassAdiposityAdultBlood GlucoseDiabetes Mellitus, Type 2FemaleFranceHumansInsulin ResistanceLipidsMaleMiddle AgedObesity, MorbidPrognosisRemission InductionRetrospective StudiesBlood GlucoseLipidsBariatric surgeryDiabetes remissionObeseType 2 diabetes mellitus

Identifiers

PMID28733906
OpenAlexW2738765305

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.